Kommentar zum Artikel „Operative Techniken und deren Outcome in der metabolischen Chirurgie: Sleeve-Gastrektomie“ von T. P. Hüttl et al.

Zusammenfassung

Der Übersichtsartikel „Operative Techniken und deren Outcome in der metabolischen Chirurgie: Sleeve-Gastrektomie“ der Kollegen Hüttl et al. beschäftigt sich mit der laparoskopischen Schlauch­magenoperation („Sleeve-Gastrektomie“) zur operativen Therapie der morbiden Adipositas (Zentralblatt für Chirurgie 2009; 134: 24–31). Nach Analyse der verfügbaren Literatur und eigener Ergebnisse kommen die Autoren zu dem Schluss, dass die laparoskopische Schlauchmagenoperation heute als ein effektiver Standardeingriff zur Therapie der Adipositas angesehen werden darf. Wir möchten ­einige Inhalte des Artikels kommentieren. 

Abstract

The review article “Operative Techniques and Outcomes in Metabolic Surgery: ­Sleeve Gastrectomy” by Hüttl et al. is con­cerned with laparoscopic sleeve stomach operations (“sleeve gastrectomy”) for the surgical treatment of morbid obesity (Zentralblatt für Chirurgie 2009; 134: 24–31). After an analysis of the available literature and own results, the authors concluded that the laparoscopic sleeve operation is established today as an effective standard procedure in the therapy for obesity. We would like to comment on the content of this article. 

Literatur

• 1 Baggio L L, Drucker D J. Biology of incretins: GLP-1 and GIP.  Gastroenterology. 2007;  132 2131-2157
• 2 Batterham R L, Cohen M A, Ellis S M et al. Inhibition of food intake in obese subjects by peptide YY3–36.  N Engl J Med. 2003;  349 941-948
• 3 Batterham R L, Cowley M A, Small C J et al. Gut hormone PYY(3–36) physiologically inhibits food intake.  Nature. 2002;  418 650-654
• 4 Buchwald H, Estok R, Fahrbach K et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.  Am J Med. 2009;  122 248-256
• 5 Couce M E, Cottam D, Esplen J et al. Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer.  Obes Surg. 2006;  16 870-878
• 6 Coupaye M, Puchaux K, Bogard C et al. Nutritional consequences of adjustable gastric banding and gastric bypass: a 1-year prospective study.  Obes Surg. 2009;  19 56-65
• 7 Cummings D E, Purnell J Q, Frayo R S et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans.  Diabetes. 2001;  50 1714-1719
• 8 Cummings D E, Weigle D S, Frayo R S et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.  N Engl J Med. 2002;  346 1623-1630
• 9 de Castro C M, de Lima Montebelo M I, Rasera Jr I et al. Effects of Roux-en-Y gastric bypass on resting energy expenditure in women.  Obes Surg. 2008;  18 1376-1380
• 10 Edwards C M, Stanley S A, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.  Am J Physiol Endocrinol Metab. 2001;  281 E 155-E 161
• 11 Edwards C M, Todd J F, Mahmoudi M et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9–39.  Diabetes. 1999;  48 86-93
• 12 English P J, Ghatei M A, Malik I A et al. Food fails to suppress ghrelin levels in obese humans.  J Clin Endocrinol Metab. 2002;  87 2984
• 13 Furnes M W, Tommeras K, Arum C J et al. Gastric bypass surgery causes body weight loss without reducing food intake in rats.  Obes Surg. 2008;  18 415-422
• 14 Guerci B, Martin C S. Exenatide: its position in the treatment of type 2 diabetes.  Ann Endocrinol (Paris). 2008;  69 201-209
• 15 Holdstock C, Engstrom B E, Ohrvall M et al. Ghrelin and adipose tissue regulatory pep­tides: effect of gastric bypass surgery in ­obese humans.  J Clin Endocrinol Metab. 2003;  88 3177-3183
• 16 Karamanakos S N, Vagenas K, Kalfarentzos F et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gas­tric bypass and sleeve gastrectomy: a pro­spective, double blind study.  Ann Surg. 2008;  247 401-407
• 17 Korner J, Bessler M, Cirilo L J et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin.  J Clin Endocrinol Metab. 2005;  90 359-365
• 18 Laferrere B, Heshka S, Wang K et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes.  Diabetes Care. 2007;  30 1709-1716
• 19 le Roux C W, Aylwin S J, Batterham R L et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic pa­ram­eters.  Ann Surg. 2006;  243 108-114
• 20 le Roux C W, Patterson M, Vincent R P et al. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects.  J Clin Endocrinol Metab. 2005;  90 1068-1071
• 21 le Roux C W, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass.  Ann Surg. 2007;  246 780-785
• 22 Lee H, Te C, Koshy S et al. Does ghrelin really matter after bariatric surgery?.  Surg Obes Relat Dis. 2006;  2 538-548
• 23 Mancini M C, Costa A P, de Melo M E et al. ­Effect of gastric bypass on spontaneous growth hormone and ghrelin release pro­files.  Obesity (Silver Spring). 2006;  14 383-387
• 24 McIntyre N, Holdsworth C D, Turner D S. New interpretation of oral glucose tolerance.  Lancet. 1964;  2 20-21
• 25 Murakami N, Hayashida T, Kuroiwa T et al. Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats.  J Endocrinol. 2002;  174 283-288
• 26 Murphy K G, Bloom S R. Gut hormones and the regulation of energy homeostasis.  Nature. 2006;  444 854-859
• 27 Nadreau E, Baraboi E D, Samson P et al. Effects of the biliopancreatic diversion on energy balance in the rat.  Int J Obes (Lond). 2006;  30 419-429
• 28 Neary N M, Small C J, Druce M R et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.  Endocrinology. 2005;  146 5120-5127
• 29 Pories W J, Albrecht R J. Etiology of type II diabetes mellitus: role of the foregut.  World J Surg. 2001;  25 527-531
• 30 Pournaras D J, le Roux C W. After bariatric surgery what vitamins should be measured and what supplements should be given?.  Clin Endocrinol (Oxf). 2009;  ,  Epub ahead of print
• 31 Rubino F, Gagner M. Weight loss and plasma ghrelin levels.  N Engl J Med. 2002;  347 1379-1381
• 32 Rubino F, Gagner M, Gentileschi P et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism.  Ann Surg. 2004;  240 236-242
• 33 Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal mod­el of type 2 diabetes: a new perspective for an old disease.  Ann Surg. 2004;  239 1-11
• 34 Stenstrom B, Zhao C M, Tommeras K et al. Is gastrin partially responsible for body weight reduction after gastric bypass?.  Eur Surg Res. 2006;  38 94-101
• 35 Tang-Christensen M, Larsen P J, Goke R et al. Central administration of GLP-1-(7-36) ­amide inhibits food and water intake in rats.  Am J Physiol. 1996;  271 (4 Pt 2) R 848-R 856
• 36 Wren A M, Seal L J, Cohen M A et al. Ghrelin ­enhances appetite and increases food intake in humans.  J Clin Endocrinol Metab. 2001;  86 5992
• 37 Wren A M, Small C J, Abbott C R et al. Ghrelin causes hyperphagia and obesity in rats.  Diabetes. 2001;  50 2540-2547